Molecular interaction of Survivin and piperine by computational docking analyses for neuroblastoma targeting

Annals of Neurosciences

Volumn 18, Issue 4, 2011, Pages 145-147

  Muthukumar, V ^a   Vanisree, A J ^a  

^a UNIVERSITY OF MADRAS   (India)

Author keywords

Childhood cancer alkaloid apoptosis in silico

Indexed keywords

HYDROGEN; PIPERINE; SURVIVIN;

AMINO ACID SEQUENCE; ARTICLE; COMPUTER MODEL; DRUG TARGETING; HYDROGEN BOND; HYDROPHOBICITY; INFORMATION PROCESSING; MOLECULAR DOCKING; MOLECULAR INTERACTION; NEUROBLASTOMA; PROTEIN INTERACTION;

EID: 80052956797     PISSN: 09727531     EISSN: 09763260     Source Type: Journal    
DOI: 10.5214/ans.0972.7531.1118404     Document Type: Article

References (21)

1. David S. Goodsell. Computational Docking of Biomolecular Complexes with AutoDock. Cold Spring Harb Protoc; 2009; doi:10.1101/pdb. prot5200.
2. Proteochemometrics.org - A Site Dedicated to the Research of Proteochemometrics. http://www.proteochemometrics.org (accessed March 12, 2008).
3. Konno R, Yamakawa H, Utsunomiya H, et al. Expression of survivin and Bcl-2 in the normal human endometrium. Mol Hum Reprod, 2000; 6: 529-34.
4. Gianani R, Jarboe E, Frost M, et al. Expression of Survivin in normal, hyperplastic, and neoplastic colonic mucosa. Hum. Pathol, 2001; 32: 119-25. Fig. 3: Interaction of ligand and protein in HB plot.
5. Altieri DC. Validating survivin as a cancer therapeutic target. Nat Rev Cancer 2003; 3: 46-54.
6. Altura RA, Olshefski RS, Jiang Y, et al. Nuclear expression of Survivin in paediatric ependymomas and choroid plexus tumours correlates with morphologic tumour grade. Br J Cancer, 2003; 3: 89(9): 1743-9.
7. Li F, Ambrosini G, Chu EY, et al. Control of apoptosis and mitotic spindle checkpoint by Survivin. Nature, 1998; 396: 580-4.
8. Altieri DC, Marchisio PC and Marchisio C. Survivin apoptosis: an interloper between cell death and cell proliferation in cancer. Lab Invest, 1999; 79: 1327-33.
9. Noton EA, Colnaghi R, Tate S, et al. Separating the anti-apoptotic and mitotic roles of Survivin. Bio. Chem, 2006; 44: 33450-6.
10. Lens SM, Coffer PJ, Burgering BM, et al. Survivin is required for a sustained spindle checkpoint arrest in response to lack of tension. EMBO J, 2003; 22: 2934-47.
11. Fangusaro JR, Jiang Y, Holloway MP, et al. Survivin, Survivin-2B, and Survivin-deIta Ex3 expression in medulloblastoma: biologic markers of tumour morphology and clinical outcome. Br. J. Cancer, 2005; 92: 359-65.
12. Wang JX and Zheng S. Caspase-3 and Survivin expression in pediatric Neuroblastoma and their roles in apoptosis. Chin Med J (Engl), 2004; 117(12): 1821-4.
13. Srinivasan K. Black pepper and its pungent principle-Piperine: a review of diverse physiological effects. Crit Rev Food Sci Nutr, 2007; 47(8): 735-48.
14. Beierle EA, Nagaram A, Dai W, et al. VEGF stimulated expression of Survivin by Neuroblastoma cells is dependent upon AKT. Journal of Surgical Research, 2004; 121(2): 305.
15. Morris GM, Goodsell DS, Halliday RS, et al. Automated Docking Using a Lamarckian Genetic Algorithm and an Empirical Binding Free Energy Function. Journal of Computational Chemistry, 1998; 19(14): 1639-1662.
16. Solis FJ and Wets RJB. Minimization by Random Search Techniques. Mathematics of Operations Research - MOR, 1981; 6(1): 19-30.
17. Bikadi Z and Hazai E. Application of the PM6 semi-empirical method to modeling proteins enhances docking accuracy of Auto Dock. J. Cheminf, 2009; 1: 15.
18. Berthold F and Hero B. Neuroblastoma: current drug therapy recommendations as part of the total treatment approach. Drugs, 2000; 59(6): 1261-77.
19. Kortemme T and Baker D. A Simple Physical Model for Binding Energy hot Spots in Protein-protein Complexes. Proc Natl Acad Sci USA 2002; 99: 14116-14121.
20. Toprakçi M and Yelekç I. K. Docking studies on monoamine oxidase-B inhibitors: Estimation of inhibition constants (Ki) of a series of experimentally tested compounds. Bioorganic & Medicinal Chemistry Letters, 2005; 15: 4438-4446.
21. Patil R, Das S, Stanley A, et al. Optimized Hydrophobic Interactions and Hydrogen Bonding at the Target-Ligand Interface Leads the Pathways of Drug-Designing. PLoS ONE, 2010; 5(8): 1-10.